Our study revealed that the oncogenic effects of YAP on HCC at least partially rely on its regulation of MAML1, suggesting that therapeutics targeting MAML1 may also attenuate the biological function of YAP. The gene discussed is YAP1; the disease is hepatocellular carcinoma.